Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NANOBIOTIX to Attend Investor Conferences in November
    NANOBIOTIX to Attend Investor Conferences in November

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972317/0/en/NANOBIOTIX-to-Participate-in-Multiple-Investor-Conferences-in-November.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome
    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920900/29248/en/Anavex-Life-Sciences-Announces-Translational-Biomarker-Data-for-ANAVEX-2-73-blarcamesine-in-Fragile-X-Syndrome-Major-Cause-of-Autism-at-the-19th-NFXF-International-Fragile-X-Confer.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    08 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/08/2805328/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Neurodevelopmental-Disorders.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share
    Anavex’s experimental drug fails Rett syndrome study, stock falls
    Anavex’s experimental drug fails Rett syndrome study, stock falls

    03 Jan 2024

    // ENDPTS

    https://endpts.com/anavexs-experimental-drug-fails-rett-syndrome-study-stock-falls/

    ENDPTS
    03 Jan 2024
    Share Share
    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine
    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine

    19 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/19/2798446/29248/en/Anavex-Received-Agreement-from-the-Committee-for-Medicinal-Products-for-Human-Use-CHMP-for-the-Submission-of-a-Marketing-Authorisation-Application-of-Oral-Blarcamesine-for-Alzheime.html

    GLOBENEWSWIRE
    19 Dec 2023
    Share Share
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    22 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/22/2784760/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Insomnia-or-Anxiety.html

    GLOBENEWSWIRE
    22 Nov 2023
    Share Share